NCI begins rewrite of cancer center grant guidelines; will allow clinical investigator support. Goal is to implement P30-P50 working group recommendations, simplify guidelines, Karen Antman tells advisory board.
NCI considers allowing some centers to opt out of site visits.
Board of Scientific Advisors discussion: Are peer reviewers correctly interpreting the guidelines?
Also in this 8-page issue: John Mendelsohn selected for BMS award. National Coalition for Cancer Survivorship and The Wellness Community begin advocacy initiative.
Business & Regulatory Report March edition (8 pages) included.
Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - With five-year cancer survival at an all-time high, does this mean people are living longer?
- Blood Cancer United: A new name at the right moment
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - In The Headlines: Is early detection always good? Inside NCI’s MCD feasibility trial.
- Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer
